Adenosine A2A receptor mRNA expression in Parkinson's disease
Adenosine A2A receptor mRNA expression in Parkinson's disease
复制标题
DOI：
10.1016/s0304-3940(00)01371-9
复制
发表时间：
2000-09-08
影响因子：
2.5
通讯作者：
Jenner, P
中科院分区：
文献类型：
--
作者：
Hurley, MJ;Mash, DC;Jenner, P
人腺苷AZA受体的表达进行了检查，通过逆转录聚合酶链反应在死后的人脑组织，从正常人和帕金森病患者死亡。腺苷阿帕受体mRNA在纹状体（中脑核、尾状核和壳核）和纹状体外（苍白球和黑质）脑区均检测到。腺苷阿帕受体mRNA的水平显着下降，发现在前，后尾状核和前背壳核，而一个显着增加，观察到在黑质网状部的帕金森病患者的大脑相比，年龄匹配的控制。腺苷阿帕受体mRNA水平在任何其他脑区检查没有变化。这项研究表明，阿帕受体mRNA的表达改变，在基底神经节的患者谁死于帕金森病和谁正在接受治疗与多巴胺能药物。腺苷阿帕受体似乎受人脑中多巴胺能系统的调节，尽管这些数据不允许区分神经元变性或药物治疗的影响。因此腺苷AZA受体可能成为治疗基底神经节疾病的靶点。(C)2000年由Elsevier Science爱尔兰有限公司出版。
The expression of the human adenosine AZA receptor was examined by reverse transcription polymerase chain reaction in post-mortem human brain tissue that was obtained from normal subjects and patients who died with Parkinson's disease. Adenosine APA receptor mRNA was detected in both striatal (nucleus accumbens, caudate nucleus and putamen) and extrastriatal (globus pallidus and substantia nigra) brain regions. A significant decrease in the level of adenosine APA receptor mRNA was found in the anterior and posterior caudate nucleus and anterior dorsal putamen, whereas a significant increase was observed in the substantia nigra pars reticulata of Parkinsonian brain when compared to agematched controls. No change in adenosine APA receptor mRNA levels was seen in any other brain region examined. This study demonstrates that APA receptor mRNA expression is altered in the basal ganglia of patients who died with Parkinson's disease and who were receiving treatment with dopaminergic drugs. The adenosine APA receptor appears subject to regulation by dopaminergic systems in human brain, though these data do not permit a distinction to be made between the effects of neuronal degeneration or drug treatment. The adenosine AZA receptor may therefore form a target for the treatment of basal ganglia disease. (C) 2000 Published by Elsevier Science Ireland Ltd.